$2.81
Insights on Nuvation Bio Inc
Revenue is up for the last 2 quarters, -694.0K → -191.0K (in $), with an average increase of 263.4% per quarter
Netprofit is up for the last 3 quarters, -20.64M → -13.78M (in $), with an average increase of 23.8% per quarter
In the last 3 years, Novo Nordisk A/s has given 242.1% return, outperforming this stock by 317.3%
0.36%
Downside
Day's Volatility :4.11%
Upside
3.77%
66.19%
Downside
52 Weeks Volatility :77.16%
Upside
32.45%
Period | Nuvation Bio Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 86.09% | -0.5% | 0.0% |
6 Months | 134.17% | 5.9% | 0.0% |
1 Year | 55.25% | 3.1% | -1.9% |
3 Years | -74.36% | 14.2% | -21.8% |
Market Capitalization | 704.3M |
Book Value | $2.76 |
Earnings Per Share (EPS) | -0.35 |
Wall Street Target Price | 5.7 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -9.65% |
Return On Equity TTM | -12.03% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -99.6M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.37 |
EPS Estimate Next Year | -0.54 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.1 |
What analysts predicted
Upside of 102.85%
Sell
Neutral
Buy
Nuvation Bio Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Nuvation Bio Inc | 24.34% | 134.17% | 55.25% | -74.36% | -71.44% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Nuvation Bio Inc | NA | NA | NA | -0.37 | -0.12 | -0.1 | NA | 2.76 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Nuvation Bio Inc | Buy | $704.3M | -71.44% | NA | 0.0% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Nuvation Bio Inc’s price-to-earnings ratio stands at None
Read Morenuvation bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. nuvation bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. nuvation bio was founded in 2018 by biopharma industry veteran david hung, m.d., who previously founded medivation, inc., which brought to patients one of the world’s leading prostate cancer medicines. nuvation bio has offices in new york and san francisco.
Organization | Nuvation Bio Inc |
Employees | 51 |
CEO | Dr. David T. Hung M.D. |
Industry | Healthcare |